Improved Gastrointestinal Tolerability Profile with Diroximel Fumarate Compared to Dimethyl Fumarate in Relapsing MS Patients (994)

Objective: null To evaluate tolerability and impact of gastrointestinal (GI) adverse events (AEs) with diroximel fumarate (DRF) versus dimethyl fumarate (DMF) in patients with relapsing-remitting multiple sclerosis (MS). null Background: null DRF is an investigational, oral fumarate for relapsing forms of MS with an improved GI tolerability profile compared to DMF. DRF 462 mg and DMF 240 mg produce bioequivalent exposure of the active metabolite...